Aurobindo Pharma Ltd. (ARBN)

Currency in INR
1,658.00
+69.10(+4.35%)
Closed·

ARBN Earnings

Latest Release
Aug 04, 2026
EPS / Forecast
17.86 / 17.33
Revenue / Forecast
91.5B / 90.3B
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
2026/09--/16.56--/94.23B----Free Sign Up
2026/0617.86/17.3391.50B/90.30B+3.06%+1.33%Free Sign Up
2026/0315.86/16.6488.53B/87.29B-4.69%+1.42%Free Sign Up
2025/1215.67/15.9086.46B/84.98B-1.45%+1.74%Free Sign Up
2025/0914.61/15.2482.86B/81.42B-4.13%+1.77%Free Sign Up
2025/0614.20/16.8378.68B/82.19B-15.63%-4.27%Free Sign Up
2025/0315.56/17.5383.82B/80.85B-11.24%+3.67%Free Sign Up
2024/1214.56/15.4279.79B/76.70B-5.58%+4.03%Free Sign Up
2024/0914.00/16.0577.96B/77.88B-12.77%+0.1%Free Sign Up
2024/0615.69/16.2375.67B/76.09B-3.33%-0.55%Free Sign Up

All numbers in INR

Aurobindo Pharma Ltd. Earnings Call Summary for Q1/2027

  • Q1 FY2027 revenue rose 16% YoY to INR 9,150 crore; EBITDA margin at 21% with full-year guidance reaffirmed above INR 8,000 crore.
  • Gross margin improved to 60.4% from 58.8%; company shifting from investment phase to monetization with better returns expected.
  • Growth markets surged 38% to INR 1,063 crore; Europe up 11% in constant currency; U.S. business grew 8.1% to INR 3,770 crore.
  • ADVAIR generic launch set for August 2027; three U.S. biosimilar filings expected within one quarter; TheraNym revenue begins 2028.
  • Lannett acquisition running at 40% capacity; management targets $150-200M TheraNym revenue by 2032 with 35-50% EBITDA margins.
Last Updated: 2026-08-06, 12:30 a/m
Read Full Transcript

FAQ

What Is Aurobindo Pharma's Earnings Per Share (TTM)?

The Aurobindo Pharma EPS (TTM) is 63.99.

When Is The Next Aurobindo Pharma Earnings Date?

Aurobindo Pharma will release its next earnings report on Nov 09, 2026.

What Is Aurobindo Pharma’s Revenue Forecasts For Upcoming Quarters?

Aurobindo Pharma’s revenue forecast is 94.23B.

How Did Aurobindo Pharma React to the Company's Latest Earnings Report?

Aurobindo Pharma reported a +3.06% EPS surprise and a +1.33% revenue surprise, comparing the latest report against analyst forecasts. The stock price changed by 3.78%, reflecting the market's response to the earnings results.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.